These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

448 related items for PubMed ID: 17629849

  • 1. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor.
    Laux V, Perzborn E, Kubitza D, Misselwitz F.
    Semin Thromb Hemost; 2007 Jul; 33(5):515-23. PubMed ID: 17629849
    [Abstract] [Full Text] [Related]

  • 2. Rivaroxaban: a novel, oral, direct factor Xa inhibitor.
    Abrams PJ, Emerson CR.
    Pharmacotherapy; 2009 Feb; 29(2):167-81. PubMed ID: 19170587
    [Abstract] [Full Text] [Related]

  • 3. Rivaroxaban. A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders.
    Perzborn E, Kubitza D, Misselwitz F.
    Hamostaseologie; 2007 Sep; 27(4):282-9. PubMed ID: 17938768
    [Abstract] [Full Text] [Related]

  • 4. [Rivaroxaban (Xarelto): efficacy and safety].
    Rosencher N, Arnaout L, Chabbouh T, Bellamy L.
    Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S22-7. PubMed ID: 19185784
    [Abstract] [Full Text] [Related]

  • 5. Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
    Biemond BJ, Perzborn E, Friederich PW, Levi M, Buetehorn U, Büller HR.
    Thromb Haemost; 2007 Mar; 97(3):471-7. PubMed ID: 17334516
    [Abstract] [Full Text] [Related]

  • 6. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.
    Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Muehlhofer E, Dierig C, Misselwitz F, Kälebo P, ODIXa-HIP Study Investigators.
    Circulation; 2006 Nov 28; 114(22):2374-81. PubMed ID: 17116766
    [Abstract] [Full Text] [Related]

  • 7. Rivaroxaban: an oral direct factor Xa inhibitor for the prevention of thromboembolism.
    Chen T, Lam S.
    Cardiol Rev; 2009 Nov 28; 17(4):192-7. PubMed ID: 19525681
    [Abstract] [Full Text] [Related]

  • 8. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
    Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, Kakkar AK, Misselwitz F, Schellong S, ODIXa-DVT Study Investigators.
    Circulation; 2007 Jul 10; 116(2):180-7. PubMed ID: 17576867
    [Abstract] [Full Text] [Related]

  • 9. [Summary and perspectives. Rivaroxaban].
    Albaladejo P.
    Ann Fr Anesth Reanim; 2008 Dec 10; 27 Suppl 3():S28-31. PubMed ID: 19185785
    [Abstract] [Full Text] [Related]

  • 10. Rivaroxaban: a new oral factor Xa inhibitor.
    Perzborn E, Roehrig S, Straub A, Kubitza D, Mueck W, Laux V.
    Arterioscler Thromb Vasc Biol; 2010 Mar 10; 30(3):376-81. PubMed ID: 20139357
    [Abstract] [Full Text] [Related]

  • 11. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin.
    Kubitza D, Becka M, Mueck W, Zuehlsdorf M.
    J Clin Pharmacol; 2006 Sep 10; 46(9):981-90. PubMed ID: 16920892
    [Abstract] [Full Text] [Related]

  • 12. [Rivaroxaban: mode of action].
    Drouet L.
    Ann Fr Anesth Reanim; 2008 Dec 10; 27 Suppl 3():S9-15. PubMed ID: 19185786
    [Abstract] [Full Text] [Related]

  • 13. Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement.
    Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Misselwitz F, Muehlhofer E, Kälebo P.
    Thromb Res; 2007 Dec 10; 120(5):685-93. PubMed ID: 17292948
    [Abstract] [Full Text] [Related]

  • 14. Rivaroxaban: an oral factor Xa inhibitor.
    Thomas TF, Ganetsky V, Spinler SA.
    Clin Ther; 2013 Jan 10; 35(1):4-27. PubMed ID: 23328267
    [Abstract] [Full Text] [Related]

  • 15. Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban.
    Morell J, Sullivan B, Khalabuda M, McBride BF.
    J Clin Pharmacol; 2010 Sep 10; 50(9):986-1000. PubMed ID: 20124518
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Oral direct factor Xa inhibitors, with special emphasis on rivaroxaban.
    Mousa SA.
    Methods Mol Biol; 2010 Sep 10; 663():181-201. PubMed ID: 20617418
    [Abstract] [Full Text] [Related]

  • 20. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.
    ROCKET AF Study InvestigatorsDuke Clinical Research Institute, Durham, NC, USA..
    Am Heart J; 2010 Mar 10; 159(3):340-347.e1. PubMed ID: 20211293
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.